Company Overview:
Protagonist Therapeutics
PTGX is a clinical-stage biotech developing peptide-based drugs in hematology, inflammatory, and metabolic diseases. Its pipeline spans polycythemia vera, psoriasis, and obesity — addressing multi-billion-dollar markets.
Pipeline & Catalysts:
Rusfertide (Polycythemia Vera) 🩸
Phase 3 VERIFY trial met all primary and secondary endpoints.
Showed reduced phlebotomy needs and improved hematocrit control.
Positions rusfertide as a first-in-class treatment and regulatory catalyst.
Icotrokinra (Psoriasis) 🌐
NDA filed for IL-23 receptor antagonist.
Approval could unlock a major dermatology revenue stream.
PN-477 (Obesity) ⚡
Expands PTGX’s reach into the fast-growing obesity market.
Strategic Advantage:
Global Takeda partnership enhances execution power.
Recent $25M milestone payment post-Phase 3 validates science & provides financial support.
Investment Outlook:
Bullish Case: Above $46–$48, driven by strong clinical data & regulatory progress.
Upside Potential: Target $78–$80, supported by trial success, NDA filings, and Takeda backing.
📢 PTGX—A high-upside biotech story with catalysts across hematology, dermatology, and obesity.
#PTGX #Biotech #ClinicalTrials #Obesity #Psoriasis #Takeda #GrowthStocks
Protagonist Therapeutics
PTGX is a clinical-stage biotech developing peptide-based drugs in hematology, inflammatory, and metabolic diseases. Its pipeline spans polycythemia vera, psoriasis, and obesity — addressing multi-billion-dollar markets.Pipeline & Catalysts:
Rusfertide (Polycythemia Vera) 🩸
Phase 3 VERIFY trial met all primary and secondary endpoints.
Showed reduced phlebotomy needs and improved hematocrit control.
Positions rusfertide as a first-in-class treatment and regulatory catalyst.
Icotrokinra (Psoriasis) 🌐
NDA filed for IL-23 receptor antagonist.
Approval could unlock a major dermatology revenue stream.
PN-477 (Obesity) ⚡
Expands PTGX’s reach into the fast-growing obesity market.
Strategic Advantage:
Global Takeda partnership enhances execution power.
Recent $25M milestone payment post-Phase 3 validates science & provides financial support.
Investment Outlook:
Bullish Case: Above $46–$48, driven by strong clinical data & regulatory progress.
Upside Potential: Target $78–$80, supported by trial success, NDA filings, and Takeda backing.
📢 PTGX—A high-upside biotech story with catalysts across hematology, dermatology, and obesity.
#PTGX #Biotech #ClinicalTrials #Obesity #Psoriasis #Takeda #GrowthStocks
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.